Bharat Immunologicals Revenue

The Macroaxis Fundamental Analysis lookup allows users to check a given indicator for any equity or select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please check also Equity Screeners to view more equity screening tools
Symbol
Refresh

Revenue Analysis

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of business and is important item when evaluating financial statements of a company. Revenues from a firm's main business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which given company operates.
Bharat Immunologicals 
Revenue 
 = 
Money Received 
Discounts and Returns 
 = 
1.28 B

About Revenue

Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can includes product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Compare to competition
Based on latest financial disclosure Bharat Immunologicals Biologicals Corp Ltd reported 1.28 B of revenue. This is much higher than that of the sector, and significantly higher than that of Revenue industry, The Revenue for all stocks is over 1000% lower than the firm.

Peer Comparison

Bharat Immunologicals Revenue Comparison
Bharat Immunologicals is currently under evaluation in revenue category among related companies.

Did you try this?

Run Price Exposure Probability Now
   

Price Exposure Probability

Analyze equity upside and downside potential for a given time horizon across multiple markets
Hide  View All  Next  Launch Price Exposure Probability
Return On Equity(11.52) %
Return On Asset(1.69) %
Profit Margin(4.18) %
Operating Margin(5.13) %
Current Valuation862.5 M
Shares Outstanding43.18 M
Price to Earning65.75 times
Price to Book2.50 times
Price to Sales0.66 times
Revenue1.28 B
Gross Profit119 M
EBITDA(56.51 M)
Net Income(53.46 M)
Cash and Equivalents152.27 M
Cash per Share3.55 times
Total Debt177.56 M
Debt to Equity0.50 times
Current Ratio1.69 times
Book Value Per Share8.21 times
Earnings Per Share(1.24) times
Market Capitalization844.17 M
Z Score2.4